PD-1/PD-L1 immunotherapy plus radiation for solid tumors
Part of Cancer, Digestive system, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether combining an immune system medicine (PD-1/PD-L1 inhibitor) with radiation can improve outcomes in people with certain solid cancers. It also looks for blood or tissue “biomarkers” that may explain who benefits most.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor diagnosis that may include head and neck cancer, lung cancer, or another solid cancer
- Your situation is either palliative treatment or, for some lung cancers, adjuvant (after earlier treatment)
- Your doctor has determined you should receive a PD-1 or PD-L1 inhibitor as standard care
- You have at least one spot that can be treated with radiation (for example, metastases), or you have already had radiation to metastases
- You are age 18 or older
- You can follow study instructions and are able to speak German for study visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether giving an immunotherapy drug (a PD-1 inhibitor) after surgery is better than giving radiation therapy for people with advanced head and neck cancer who had a complete response to chemotherapy and immunotherapy before surgery. The goal is to prevent the cancer from coming back.
This trial compares two different treatments for people who have already had surgery for advanced head and neck cancer and responded very well to chemotherapy plus immunotherapy before surgery. It tests whether continuing with immunotherapy or receiving radiation therapy is better at preventing the cancer from coming back.
This study tests if adding an immunotherapy drug (PD-1 inhibitor) to chemotherapy and specially planned radiation works better for stage 3 lung cancer that cannot be surgically removed. It may be an option if you have not had previous treatment for this cancer.
This study tests a combination treatment for people with advanced solid tumors that have not responded to standard therapies. It uses a type of radiation therapy (PRaG) together with another treatment, and is specifically looking at people who have a low level of lymphocytes in their blood, which may affect how well the treatment works.
This trial tests a combination of immunotherapy (PD-1) and chemotherapy for people with advanced head and neck cancers that are poorly differentiated. The goal is to see if the combination helps shrink tumors before possible surgery or radiation.
This study looks at combining radiation therapy with immunotherapy for advanced breast cancer that has spread or cannot be surgically removed. The goal is to see if adding radiation after treatment helps improve outcomes.
Hear when a new HNSCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.